Trinity Biotech (TRIB) Current Assets (2009 - 2025)

Trinity Biotech has disclosed Current Assets across 17 years of filings, most recently posting $35.9 million for Q4 2025.

• Current Assets for Q4 2025 came in at $35.9 million, down 12.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $35.9 million (down 12.7% YoY), and the FY2025 annual result was $35.9 million, down 12.7% from the prior year.
• Current Assets came in at $35.9 million for Q4 2025 at Trinity Biotech, up from $33.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $87.6 million in Q1 2021 to a low of $33.0 million in Q2 2025.
• The 5-year median for Current Assets is $48.3 million (2022), against an average of $54.1 million.
• Across the five-year window, Current Assets grew 29.85% in 2021 and slumped 36.31% in 2022, its largest moves.
• Trinity Biotech's Current Assets stood at $72.7 million in 2021, then tumbled by 35.8% to $46.7 million in 2022, then declined by 16.34% to $39.0 million in 2023, then grew by 5.34% to $41.1 million in 2024, then fell by 12.7% to $35.9 million in 2025.
• The last three Current Assets figures came in at $35.9 million (Q4 2025), $33.0 million (Q2 2025), and $41.1 million (Q4 2024), per Business Quant data.